RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Phathom Pharmaceuticals Stock

Phathom Pharmaceuticals P/E 2024

Phathom Pharmaceuticals P/E

-1.47

Ticker

PHAT

ISIN

US71722W1071

WKN

A2PT0F

As of Sep 8, 2024, Phathom Pharmaceuticals's P/E ratio was -1.47, a -50.34% change from the -2.96 P/E ratio recorded in the previous year.

The Phathom Pharmaceuticals P/E history

Phathom Pharmaceuticals Aktienanalyse

What does Phathom Pharmaceuticals do?

Phathom Pharmaceuticals Inc. is a pharmaceutical company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. The company is headquartered in Florham Park, New Jersey and was founded in 2016. The company's business model is focused on utilizing its innovative technology and expertise in the medical treatment of gastrointestinal disorders to improve the lives of patients. It works closely with doctors and hospitals to ensure that its products are developed to the highest standards. The company is divided into different business segments to enable optimal patient care and market penetration. The key business segments are: 1. Gastroesophageal reflux disease Phathom has developed a medication called Vonoprazan for the treatment of gastroesophageal reflux disease. This common condition occurs when stomach acid flows back into the esophagus, causing pain, inflammation, and heartburn. The medication blocks the production of stomach acid, thus helping to relieve the symptoms of reflux disease. 2. Helicobacter pylori infection The company has also developed a medication called Ryzodeg for the treatment of Helicobacter pylori infection. This infection, caused by a type of bacteria, can lead to stomach ulcers and other gastrointestinal disorders. Ryzodeg is a combination of an antimicrobial substance and a proton pump inhibitor, which together are more effective than individual medications. 3. Eosinophilic esophagitis Phathom is currently developing a medication for the treatment of eosinophilic esophagitis (EoE), an allergic inflammation of the esophagus that can cause difficulty swallowing, pain, and diarrhea. The medication is currently in the clinical development phase and could soon be on the market. Phathom Pharmaceuticals was founded by a group of experienced executives from the pharmaceutical and biotech industry, including CEO Dr. Azmi Nabulsi and COO Dr. Tuan Ha-Ngoc. Both have extensive experience in the development and marketing of medications and contribute their expertise to the company's management. The company also specializes in partnerships with other pharmaceutical companies and clinical research institutions to advance its research and development. For example, the company has entered into a strategic partnership with Takeda Pharmaceuticals to advance the development and marketing of Vonoprazan. Phathom Pharmaceuticals is a promising company specializing in the development and marketing of medications for the treatment of gastrointestinal disorders. With its innovative technology and experienced management, the company is expected to continue growing in the future and help improve the health of patients around the world. Phathom Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Phathom Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Phathom Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Phathom Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Phathom Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Phathom Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Phathom Pharmaceuticals stock

What is the price-to-earnings ratio of Phathom Pharmaceuticals?

The price-earnings ratio of Phathom Pharmaceuticals is currently -1.47.

How has the price-earnings ratio of Phathom Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Phathom Pharmaceuticals has increased by -50.34% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Phathom Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Phathom Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Phathom Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Phathom Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Phathom Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Phathom Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Phathom Pharmaceuticals?

Some factors that influence the price-earnings ratio of Phathom Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Phathom Pharmaceuticals pay?

Over the past 12 months, Phathom Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phathom Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phathom Pharmaceuticals?

The current dividend yield of Phathom Pharmaceuticals is .

When does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phathom Pharmaceuticals?

Phathom Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phathom Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phathom Pharmaceuticals located?

Phathom Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phathom Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phathom Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Phathom Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Phathom Pharmaceuticals in the year 2023?

In the year 2023, Phathom Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phathom Pharmaceuticals pay out the dividend?

The dividends of Phathom Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Phathom Pharmaceuticals

Our stock analysis for Phathom Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phathom Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.